Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.
- Author:
Liming CHEN
1
;
Xiaoyan XING
2
;
Minxiang LEI
3
;
Jie LIU
4
;
Yongquan SHI
5
;
Pengqiu LI
6
;
Guijun QIN
7
;
Chengjiang LI
8
;
Yukun LI
9
;
Qing WANG
10
;
Tianshu GAO
11
;
Ling HU
12
;
Yangwei WANG
13
;
Wenying YANG
14
Author Information
- Publication Type:Journal Article
- MeSH: Administration, Oral; Adult; Aged; Biphasic Insulins; administration & dosage; adverse effects; therapeutic use; Blood Glucose; drug effects; Diabetes Mellitus, Type 2; blood; drug therapy; Female; Glycated Hemoglobin A; metabolism; Humans; Hypoglycemic Agents; therapeutic use; Insulin Aspart; administration & dosage; adverse effects; therapeutic use; Insulin, Isophane; administration & dosage; adverse effects; therapeutic use; Male; Middle Aged; Prospective Studies
- From: Chinese Medical Journal 2014;127(2):208-212
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDThe effectiveness and safety of initiating biphasic insulin aspart 30 in patients who were poorly controlled on oral glucose-lowering drugs were studied in randomized controlled trials, while results from clinical practice remain limited. This subgroup analysis was to provide such findings from a large-scale non-interventional study.
METHODSA1chieve was a multinational, prospective, open-label, non-interventional, 24-week study in patients with type 2 diabetes initiating insulin analogues in 28 countries across Asia, Africa, Europe, and Latin America. After physician had taken the decision to use this insulin, any patient with type 2 diabetes who was not treated with or who had started the study insulin within 4 weeks before inclusion was eligible. Patients were treated with study insulin alone or in combination with oral glucose-lowering drugs. Data on adverse drug reactions, hypoglycemia and glycemic control were collected at baseline, week 12 and 24. This is a report of a Chinese subgroup analysis from the A1chieve study.
RESULTSTotally, 4 100 patients constituted this subgroup. No serious adverse drug reactions were reported. Rates of total, major, nocturnal hypoglycemic events (events/patient per year) were 1.47, 0.10, 0.31 at baseline and 1.35, 0.00, 0.22 at week 24, respectively. Glycemic control was improved as measured by hemoglobin A1c (mean 9.3% to 7.0%, reduction -2.3%), fasting plasma glucose (mean 10.2 to 6.8 mmol/L, reduction -3.5 mmol/L) and postprandial plasma glucose (mean 14.4 to 8.8 mmol/L, reduction -5.6 mmol/L), all P < 0.001. Change in mean body weight was +0.3 kg (P < 0.001).
CONCLUSIONIn this subgroup analysis of the A1chieve study, biphasic insulin aspart 30 improved glycemic control with low risk of hypoglycemia.
